Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

raltegravir

- PMLiVE

ViiV bags US approval for HIV blockbuster-in-waiting

Drug combines antiretrovirals with Tivicay

- PMLiVE

US panel backs pneumococcal vaccines for seniors

Vaccines to be provided by Merck & Co and Pfizer

- PMLiVE

FDA approves Merck’s insomnia drug

Belsomra is first orexin receptor antagonist available in US

- PMLiVE

Merck & Co taps music industry for US HIV campaign

Pharma company to work with music promoter Maria Davis and Positive Women’s Network – USA

- PMLiVE

Celgene’s cancer drug promising in small HIV study

Lymphoma therapy Istodax shows potential in treating the virus

- PMLiVE

Failed HIV cure can’t dent spirit at Melbourne conference

Still 'feasible' to end Aids epidemic by 2030

- PMLiVE

Pharma joins tributes to Aids researchers lost on flight MH17

Toll of Malaysian Airlines jet crash in Ukraine includes 'HIV hero' Dr Joep Lange

- PMLiVE

Merck could win anti-PD1 therapy race in Europe

EMA accepts filing for promising pembrolizumab in melanoma

- PMLiVE

Merck & Co extends med ed portal to India

Pharma company makes Univadis accessible to yet more healthcare professionals

- PMLiVE

Merck agrees $3.85bn deal for hepatitis specialist Idenix

Opens up direct challenge to Gilead

- PMLiVE

ASCO: Merck’s anti-PD1 impresses in skin and lung cancer

Promising MK-3475 immunotherapy to be known as pembrolizumab

- PMLiVE

Bruno Strigini leaves Merck & Co for Novartis

Will head up an oncology business boosted by the acquisition of GSK's portfolio

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links